Asahi Kasei Pharma starts Phase III study of CIPN prevention therapy EP News Bureau Jul 2, 2025 Previous Phase I and II studies suggest efficacy and patient tolerability of ART-123 for CIPN by suppressing the activation of…
Asahi Kasei Pharma enters into exclusive license agreement for anti-CX3CR1 Antibody EP News Bureau Dec 11, 2024 The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell…
